Diabetes

Provo, UT

67 Diabetes Trials near Provo, UT

Power is an online platform that helps thousands of Diabetes patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

FAMS-T1D Support Program for Type 1 Diabetes

Salt Lake City, Utah
This trial tests a program called FAMS-T1D that helps young adults with type 1 diabetes manage their condition. The program includes regular coaching calls, frequent text messages, and optional support from a friend or family member. The goal is to improve blood sugar control and reduce diabetes-related stress by providing consistent advice and encouragement.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 24

280 Participants Needed

Shared Decision-Making Intervention for Gestational Diabetes

Salt Lake City, Utah
Our goal is to test whether shared decision making for diabetes prevention can help women with a history of gestational diabetes mellitus (GDM) who are at high risk of developing type 2 diabetes (T2DM) increase weight loss and adoption of evidence based strategies to lower their risk of incident diabetes.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 54
Sex:Female

310 Participants Needed

Rifampin for Osteomyelitis in Diabetics

Salt Lake City, Utah
The purpose of this research study is to determine if rifampin, an antibiotic (a medicine that treats infections), is effective in treating osteomyelitis (infection of the bone) of the foot in diabetic patients. Despite use of powerful antibiotics prescribed over a long period of time, many diabetic patients remain at a high risk for needing an amputation of part of the foot or lower leg because the osteomyelitis is not cured. Some small research studies have shown that addition of rifampin to other antibiotics is effective in treating osteomyelitis in both diabetics and non-diabetics. However, because few diabetics with osteomyelitis have been studied, there is no definite proof that it is better than the usual treatments for diabetic patients. If this study finds that adding rifampin to the usual antibiotics prescribed for osteomyelitis reduces the risk for amputations, doctors will be able to more effectively treat many Veteran patients with this serious infection. Improving treatment outcomes is an important healthcare goal of the VA.
Stay on current meds

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 4

843 Participants Needed

Shock-Absorbing Prosthesis for Leg Amputation

Salt Lake City, Utah
The goal of this project is to understand the factors that affect skin temperature (e.g., tissue above amputation site, and opposite foot) in people with amputation and diabetes. This project will also test the effects of 'shock-absorbing' prosthesis on skin temperature responses.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:19+

60 Participants Needed

Lower Radiotherapy Dose for Brain Tumors

Salt Lake City, Utah
This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \& Etoposide) works in treating children with central nervous system (CNS) germinomas. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Researchers want to see if lowering the dose of standard radiotherapy (RT) after chemotherapy can help get rid of CNS germinomas with fewer long-term side effects.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:3 - 29

240 Participants Needed

Lifestyle Coaching for Weight Loss

Salt Lake City, Utah
Many people struggle not only to lose weight through changes in diet and physical activity, but also to maintain weight loss once they have achieved it. In a previous study, our team designed and deployed a weight maintenance intervention that was delivered through the patient portal of an electronic health record (EHR) and found that patients who tracked their weight, diet, and physical activity and also received coaching had better success with maintaining recent intentional weight loss than patients who tracked but did not receive coaching. The investigators propose to repeat the intervention in a new health care system and train routine health care staff (e.g., medical assistants and nurses) to be coaches, a more sustainable model that will allow ongoing intervention delivery after the proposed study ends. This is a pragmatic randomized clinical Trial with percent weight change at 24 months as the primary outcome. This will be a 2-arm randomized trial that compares the MAINTAIN PRIME lifestyle coaching intervention to a control tracking intervention.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

269 Participants Needed

Timing of Resistance Exercise for Insulin Sensitivity

Salt Lake City, Utah
The primary aim of this study is to evaluate if a single bout of AM vs PM resistance exercise has different effects on insulin sensitivity and sleep. A randomized cross-over trial be used to compare resistance exercise at two different times of the day. Each condition will take place in a laboratory setting. Each condition will consist of exercise, overnight sleep, and oral glucose tolerance tests the following day. The AM exercise will occur \~1.5 hours after habitual wake, and PM exercise will occur \~11 hours after habitual wake. After a 2-6 week washout, participants will complete the other condition. The hypothesis is that PM exercise will be more beneficial than AM exercise in improving insulin sensitivity. This study could identify if there is a better time of day to perform resistance exercise to decrease risk of developing Type 2 Diabetes Mellitus.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:50 - 74

20 Participants Needed

NEW Diabetes and Pain Medication Study

Salt Lake City, Utah
This trial tests a daily pill called NRD135S.E1 for people with painful nerve damage from diabetes. The study will see if taking this pill for a few months can safely reduce their pain. Researchers aim to understand how well the drug works and if it is safe to use.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

122 Participants Needed

Empagliflozin for Dialysis Patients with Kidney Failure

Salt Lake City, Utah
The purpose of this study is to find out if empagliflozin, a new diabetic medication that has been shown to be very effective in lowering the risk of heart failure, is safe and tolerated in dialysis patients. In the recent years, empagliflozin has become a major tool to prevent heart failure hospitalization and to reduce the risk for cardiovascular death in diabetic and non-diabetic patients. Although patients with severe chronic kidney disease and ESKD have very high risk of heart failure and cardiovascular death, they have been excluded from all of the previous studies. If this medication is found to be well tolerated and safe in dialysis patients through this study, future clinical studies can evaluate if this medication can also reduce the risk of heart failure and cardiovascular death in dialysis patients.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1

62 Participants Needed

Sleep Extension for Obesity

Salt Lake City, Utah
The overall goal is to determine how a sleep extension intervention (increasing time in bed) in individuals who maintain less than 6.5 hours sleep per night affects their plasma ceramides and insulin sensitivity. Participants will undergo a randomized controlled trial, with sleep extension (intervention) and healthy lifestyle (control) groups. The sleep extension is designed to increase participant's time in bed by 2 hours per night. Alternatively, the control group will receive basic health information (e.g., physical activity, goal setting, and nutrition when eating out).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 45

70 Participants Needed

Circadian Intervention for Obesity

Salt Lake City, Utah
The overall goal is to examine the efficacy of a circadian intervention in people with overweight and obesity and habitual short sleep duration (HSSD). Participants will undergo a randomized controlled trial, with circadian intervention and control (healthy lifestyle) groups. The circadian intervention is designed to reduce nighttime light exposure and after-dinner snack food intake. Alternatively, the control group will receive basic health information (e.g., physical activity, goal setting, and nutrition when eating out).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 45

20 Participants Needed

AU-007 for Advanced Cancer

Salt Lake City, Utah
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin was determined, (AU-007 Q2w plus a single loading dose of aldesleukin), AU-007 plus aldesleukin is also being administered with avelumab or nivolumab.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

159 Participants Needed

Bionic Pancreas for Cystic Fibrosis

Salt Lake City, Utah
This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using their usual care insulin delivery method and continuous glucose monitoring (CGM) during a 13-week study period in individuals ≥14 years old with cystic fibrosis-related diabetes (CFRD). After 13 weeks, participants will continue in a 13-week Extension Phase in which the BP group will continue to use the BP system and the Usual Care group will initiate use of the BP system.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:14+

150 Participants Needed

IcoSema for Type 2 Diabetes

Bountiful, Utah
This trial will compare IcoSema, a new treatment combining two medicines, to insulin glargine in people with type 2 diabetes. The study targets those whose blood sugar isn't controlled by other oral medicines. IcoSema helps the body use sugar more effectively and reduces appetite to manage blood sugar levels. Insulin glargine is a long-acting insulin commonly used with oral antidiabetic drugs to improve blood sugar control in patients with type 2 diabetes.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

474 Participants Needed

Maridebart Cafraglutide for Obesity

Layton, Utah
The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

1105 Participants Needed

Retatrutide for Type 2 Diabetes and Obesity

Ogden, Utah
This trial is testing retatrutide, a medication for people with type 2 diabetes who are overweight or obese, including some with sleep apnea. The medication aims to help control blood sugar levels and may also aid in weight loss.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

1000 Participants Needed

SAR442970 for Type 1 Diabetes

Ogden, Utah
This is a randomized, placebo-controlled, parallel group, multicenter, double-blind Phase 2a, 2-arm study. The goal of this Phase 2a study is to assess safety and efficacy of SAR442970 in comparison to placebo to preserve β-cell function in participants with recently diagnosed type 1 diabetes (T1D) on insulin therapy. The study design comprises 2 parts: in Part A adult participants (18 to 35 years of age at screening) and in Part B adolescent and young adult participants (age range 12 to 21 years) will be randomized into SAR442970 and placebo groups. Approximately 84 participants will be included with randomization ratio 3:1 (active:placebo). The study includes a screening period (3 to 5 weeks), a double-blind treatment period of 52 weeks and a safety follow-up of 26 weeks.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:12 - 35

84 Participants Needed

Weekly vs Daily Insulin for Type 1 Diabetes

Ogden, Utah
This study compares insulin icodec, an insulin taken once a week to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 1 diabetes. The study will look at how well insulin icodec taken weekly controls blood sugar compared to insulin glargine taken daily. The study will last for about 8.5 months.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

877 Participants Needed

Treatment for Type 1 Diabetes

Ogden, Utah
This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.
Stay on current meds
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

150 Participants Needed

EYE103 for Diabetic Macular Edema

West Jordan, Utah
EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME). In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm. Approximately 960 participants will be entered in the study.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2, 3

960 Participants Needed

Why Other Patients Applied

"I have had type 2 diabetes for some time now and would love to be part of a study... should the study drug work out as a successful treatment, then I would be glad to be one of the first patients in line!"

MB
Diabetes PatientAge: 67

"Years ago, Metformin didn't help. I'm currently on Rybelsus & Farxiga. Not doing me much good. My insurance won't cover any of the injectables. Excited to try something new."

QL
Diabetes PatientAge: 71

"I've been in pain for years. It's been crippling and has massively impacted my life. I want to be free. Diabetes changed everything at 15. Diabetic Type 1 for 20 years. SEVERE Peripheral Neuropathy onset 7-8 years in. Have been living with it since. Have tried every drug, everything. Gaba, lyrica, all opioids, electrical current therapy, massages, acupuncture, cupping, everything. Currently taking low dose of duloxetine, have an insulin pump but its not good enough. Want to try a cutting-edge med."

YN
Diabetes PatientAge: 35

"I have struggled with weight management after having bariatric surgery over 5 years ago and have regained what I have lost. I'm looking to participate in a trial that can help me get my life back under control."

IJ
Diabetes PatientAge: 25

"I have already lost part of a leg to an infection. I want to try to get this horrific condition under control and get back to my life. It's taken enough."

WY
Diabetes PatientAge: 40

Suzetrigine for Diabetic Neuropathy

West Jordan, Utah
The purpose of this study is to evaluate the long-term safety and tolerability of SUZ and long-term effectiveness of SUZ in treating pain associated with DPN.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 3

300 Participants Needed

Suzetrigine for Diabetic Neuropathy

West Jordan, Utah
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

1100 Participants Needed

LY3556050 for Diabetic Peripheral Neuropathic Pain

West Jordan, Utah
This trial is testing a new drug called LY3556050 to see if it can help reduce nerve pain in people with diabetes. The study will last several months and will compare the effects of LY3556050 to another treatment. The goal is to determine if LY3556050 is safe and effective for treating diabetic nerve pain.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

410 Participants Needed

RTA 901 for Diabetic Neuropathy

West Jordan, Utah
This trial is testing a new drug called RTA 901 to see if it can help people with nerve pain caused by diabetes. The drug likely works by calming down the nerves that are causing the pain. The study will compare different doses of the drug to find out which dose works best.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

384 Participants Needed

RO7497372 for Diabetic Macular Edema

West Jordan, Utah
This study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-ascending doses of RO7497372 after unilateral intravitreal (IVT) administration in participants with DME. The main purpose of Part 1 is to provide data for RO7497372 safety and tolerability, as well as to characterize the ocular and systemic pharmacokinetics (PK), systemic anti-drug antibodies (ADA), and duration of target engagement, i.e., the pharmacodynamics (PD) in aqueous humor (AH) and blood. Part 2 will evaluate the safety, tolerability, PK, and PD of two dose strengths of RO7497372 (low dose and high dose), identified as safe and tolerated in Part 1.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

176 Participants Needed

PDS with Ranibizumab vs. Intravitreal Ranibizumab for Diabetic Macular Edema

Salt Lake City, Utah
This study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal (IVT) ranibizumab 0.5 milligrams (mg) every 4 weeks (Q4W). The substudy will evaluate safety of re-implanting the updated PDS with ranibizumab and the refill-exchange procedures following re-implantation in participants with DME who were previously enrolled in the main study, GR40550. Up to 100 participants from the main study will be enrolled and followed for a maximum of 72 weeks post-re-implantation in the substudy.
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

634 Participants Needed

Ranibizumab PDS Implant for Diabetic Retinopathy

Murray, Utah
Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DME) to Evaluate the Efficacy, Safety of the Port Delivery System with Ranibizumab (PDS) Relative to the Comparator Arm
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting

174 Participants Needed

LX9211 for Diabetic Neuropathy

Salt Lake City, Utah
This trial is testing a new drug called LX9211 to see if it can reduce nerve pain in people with diabetes. The drug works by blocking pain signals in the nerves. Researchers want to find out if it is more effective than other treatments. A similar drug was previously tested for similar conditions but its development was halted due to safety concerns.

Trial Details

Trial Status:Active Not Recruiting

416 Participants Needed

OptiPulse™ for Diabetic Foot Ulcers

Salt Lake City, Utah
This trial tests the safety and effectiveness of OptiPulse™, a device that improves blood flow, in treating diabetic foot ulcers. It aims to see if this device helps heal these ulcers better than standard treatments.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

100 Participants Needed

Finerenone for Chronic Kidney Disease

South Salt Lake, Utah
This trial is testing finerenone, a daily pill, to help people with non-diabetic chronic kidney disease. Finerenone works by blocking a hormone called aldosterone that can cause damage and swelling in the heart and kidneys. The goal is to see if finerenone can slow down the worsening of kidney disease. Finerenone has shown promise in reducing kidney disease progression in patients with chronic kidney disease and type 2 diabetes.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

1584 Participants Needed

123

Know someone looking for new options? Spread the word

Match to a Trial